证券代码：000623 证券简称：吉林敖东 债券代码：127006 债券简称：敖东转债 吉林敖东药业集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |--------------------|----------------------------------------------------------------------|----------------------------|----------------------| | | | | 编号：2023-007 | | | □特定对象调研 □分析师会议 | | | | 投资者关系活动类别 | □媒体采访 √业绩说明会□新闻发布会 □路演活动□现场参观 | | | | | □其他 | （请文字说明其他活动内容） | | | 参与人员及方式 | 投资者网上提问 | | | | 时间 | 2023 年 5 月 22 日 | （周一）下午 14:30~16:00 | | | 地点 | 公司通过全景网"投资者关系互动平台"（采用网络远程的方式召开业绩说明会 | | https://ir.p5w.net） | | ...

证券代码：000623 证券简称：吉林敖东 债券代码：127006 债券简称：敖东转债 吉林敖东药业集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |--------------------|------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------| | | | | 编号：2023-006 | | | □特定对象调研 □分析师会议 | | | | 投资者关系活动类别 | □媒体采访 □业绩说明会□新闻发布会 √路演活动□现场参观 | | | | | □其他 | （请文字说明其他活动内容） | | | | 现场及网络通信方式 | | | | 参与人员及方 | 西部证券：罗钻辉、孙冀齐 | | | | 式 | 银华基金：华强强 | | | | | 平安养老：叶华 | | | | 时间 | 2023 年 5 月 10 日 ...

| 证券代码:000623 | 证券简称:吉林敖东 | 公告编号:2023-030 | | --- | --- | --- | | 债券代码:127006 | 债券简称:敖东转债 | | 届时公司副董事长、总经理郭淑芹女士，董事、副总经理杨凯先生，董事、 副总经理、财务总监张淑媛女士，董事、副总经理、董事会秘书王振宇先生，将 通过网络在线问答互动的形式，与投资者就2022年经营业绩等投资者关注的问题 进行交流。期间，公司高管将全程在线，实时回答投资者的提问。投资者可于2023 年5月19日（星期五）17：00前访问https://ir.p5w.net/zj/，或扫描下方二维 码，进入问题征集专题页面，欢迎广大投资者积极参与。 （问题征集专题页面二维码，扫码自动匹配移动端） 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2023年5月13日 为进一步加强与投资者的互动交流，吉林敖东药业集团股份有限公司（以下 简称"公司"）将参加由吉林证监局、吉林省证券业协会、深圳市全景网络有限 公司共同举办的"2023年吉林辖区上市公司网上集体业绩说明会"，现将有关事 项公告 ...

证券代码：000623 证券简称：吉林敖东 债券代码：127006 债券简称：敖东转债 吉林敖东药业集团股份有限公司 投资者关系活动记录表 | --- | --- | |--------------------|----------------------------------------------------------| | | √特定对象调研 □分析师会议 | | 投资者关系活动类别 | □媒体采访 □业绩说明会□新闻发布会 □路演活动□现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与人员及方式 | 线上调研方正证券：唐爱金、章钟涛富荣基金：杨皓童、李天翔 | | 时间 | 2023 年 5 月 8 日 | | 地点 | 吉林省敦化市敖东大街 | | 上市公司接待 | | | 人员姓名 | 董事、副总经理、董事会秘书：王振宇 | | | 1、公司简介 | | | 公司的前身是 1957 | | | 年建立敖东制药厂， | | | | | | 吉林敖东药业集团股份有限公司， | | | 挂牌上市。共控股 6 | | | 药的专业制药子公司，1 | | | 司，6 家医药配套子公司 ...

证券代码：000623 证券简称：吉林敖东 债券代码：127006 债券简称：敖东转债 吉林敖东药业集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |--------------------|------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------| | | √特定对象调研 □分析师会议 | | | | 投资者关系活动类别 | □媒体采访 □业绩说明会□新闻发布会 □路演活动√现场参观 | | | | | □其他 （请文字说明其他活动内容） | | | | | 现场参观调研 | | | | 参与人员及方 | 苏民投：耿岩 | | | | 式 | 红思客：杨岌 | | | | | 个人投资者：高鹏 | | | | 时间 | 2023 年 5 月 6 日 | | | | 地点 | ...

Financial Position - Total assets at the end of the reporting period reached ¥31,527,982,345.33, an increase of 1.14% compared to the end of the previous year[4] - Equity attributable to shareholders of the listed company was ¥26,541,678,212.19, reflecting a growth of 1.94% year-over-year[4] - Cash and cash equivalents amounted to ¥1,115,315,423.74, down from ¥1,438,410,359.55 at the beginning of the year[18] - Accounts receivable increased to ¥859,896,462.76 from ¥688,507,719.81, indicating a significant rise in receivables[18] - Inventory stood at ¥882,342,196.84, slightly up from ¥874,566,422.45 at the start of the year[18] - Non-current assets totaled ¥25,615,849,796.55, compared to ¥25,190,598,142.50 at the beginning of the year[19] - Short-term borrowings increased to ¥700,945,060.24 from ¥651,268,157.68, indicating a rise in debt levels[19] - Total liabilities decreased slightly, with accounts payable at ¥400,584,382.68, down from ¥436,811,348.05[19] - The total liabilities amounted to ¥4,678,079,303.76, a slight decrease from ¥4,832,458,153.80 in the previous year[20] - Total equity attributable to shareholders of the parent company increased to ¥26,541,678,212.19, compared to ¥26,036,572,752.10 in the previous year[20] Financial Performance - The company's operating revenue for the current period reached ¥787,662,853.93, representing a 23.64% increase compared to the same period last year[25] - Net profit attributable to shareholders of the listed company was ¥485,778,761.52, a significant increase of 719.23% year-over-year[25] - The net profit after deducting non-recurring gains and losses was ¥445,080,877.24, reflecting a 72.67% increase compared to the previous year[25] - Basic earnings per share rose to ¥0.4311, marking a 727.45% increase from the same period last year[25] - The weighted average return on net assets improved to 1.85%, up from 0.24% in the previous year[25] - The net profit for the current period is ¥490,454,966.00, a significant increase from ¥54,983,604.36 in the previous period[35] - The operating profit for the current period is ¥516,743,967.27, compared to ¥3,355,653.17 in the previous period[35] Cash Flow - The net cash flow from operating activities was negative at -¥230,225,528.25, worsening by 118.48% compared to the previous year[25] - Operating cash inflow from sales of goods and services was approximately $500.49 million, up from $376.92 million year-over-year, showcasing improved cash generation[37] - The net cash flow from operating activities was negative at approximately -$230.23 million, worsening from -$105.37 million in the previous period, highlighting challenges in cash management[41] - Cash flow from investing activities showed a significant inflow of approximately $4.78 billion, compared to $656.57 million in the previous period, indicating aggressive investment strategies[41] - The net cash flow from financing activities was negative at approximately -$476.53 thousand, a decline from a positive inflow of $71.56 million in the previous period, suggesting increased financial pressures[44] - The cash and cash equivalents at the end of the period were approximately $1.12 billion, down from $1.65 billion in the previous period, reflecting liquidity challenges[44] Other Information - The company reported no non-recurring gains or losses during the reporting period[5] - The company confirmed that the financial information in the quarterly report is true, accurate, and complete[10] - The company received government subsidies amounting to ¥14,190,542.33 during the reporting period[27] - The company's contract liabilities decreased by 74.58% to ¥20,912,581.63 from ¥82,254,297.15, due to revenue recognition from previously received payments[28] - The fair value change income increased by 111.53% to ¥32,929,127.06 from a loss of ¥285,574,862.48, attributed to the increase in fair value of trading financial assets[35] - The company's total liabilities due within one year increased dramatically by 12,772.20% to ¥2,347,208,407.58 from ¥18,234,717.47, mainly due to convertible bonds maturing within a year[28] - The company's research and development expenses increased to ¥13,041,154.70 from ¥10,666,492.74, reflecting ongoing investment in new technologies[35] - The total number of ordinary shareholders at the end of the reporting period is 72,741[29] - The net profit attributable to the parent company was approximately $485.78 million, a significant increase from $59.30 million in the previous period, reflecting a strong performance[36] - The total comprehensive income attributable to the parent company reached approximately $505.09 million, compared to a loss of $3.19 million in the previous period, indicating a positive turnaround[36] - The company reported a total comprehensive income of approximately $509.76 million, compared to a loss of $7.50 million in the previous period, indicating a strong recovery[36] - The company received approximately $2.73 million in tax refunds, down from $5.94 million in the previous period, indicating changes in tax recovery dynamics[41]

Fundraising and Investment - The total amount of funds raised in 2018 was CNY 238,853.87 million, with CNY 9,334.48 million used in the current period and CNY 170,840.93 million used cumulatively[5]. - The investment progress for the Jilin Aodong Yanjin Pharmaceutical Co., Ltd. expansion project is 74.25%, with a total committed investment of CNY 85,200.00 million and CNY 30,442.77 million invested to date[6]. - The Jilin Aodong Shihang Pharmaceutical Co., Ltd. smart factory project for traditional Chinese medicine has achieved an investment progress of 100.95%, with a total investment of CNY 9,000.00 million and CNY 9,079.44 million invested cumulatively[6]. - The company has committed to a total investment of CNY 241,300.00 million across various projects, with CNY 238,853.87 million already raised and CNY 170,840.93 million used cumulatively[7]. - The company has adjusted the use of raised funds, with CNY 50,974.83 million allocated to supplement working capital for the Jilin Aodong Yanjin Pharmaceutical Technology Park project[10]. - The company aims to achieve a 100% investment progress in various projects, with some projects already reaching their expected benefits[10]. Financial Performance - The company's total assets reached CNY 31,172.58 million, an increase of CNY 2,105.18 million, or 7.24% from the beginning of the year[40]. - Net assets attributable to shareholders increased to CNY 26,036.58 million, up CNY 1,177.10 million, or 4.73%[40]. - The asset-liability ratio stands at 15.50%[40]. - Operating revenue amounted to CNY 2,868.21 million, an increase of CNY 564.45 million, or 24.50% year-on-year[40]. - Net profit attributable to shareholders was CNY 1,780.64 million, a slight increase of CNY 14.22 million, or 0.01%[40]. - The total revenue for the core products in 2022 reached CNY 99,407.09 million, an increase of 17.97% compared to CNY 84,265.20 million in 2021[92]. - The company reported a net profit of CNY 1,745,761,178.52 for the year 2022, with a statutory surplus reserve of CNY 174,576,117.85 deducted[112]. - The total distributable profit as of December 31, 2022, amounted to CNY 17,698,534,461.32, after accounting for cash dividends and other adjustments[112]. - The total cash dividend, including share buybacks, is CNY 508,120,106.67, representing 28.54% of the net profit attributable to shareholders for 2022[112]. Revenue Breakdown - Revenue from traditional Chinese medicine reached CNY 1,692.48 million, a year-on-year growth of 14.92% due to enhanced channel management[41]. - Revenue from chemical drugs was CNY 325.48 million, a decline of 4.30% attributed to decreased sales of core products[41]. - Revenue from chain pharmacy wholesale and retail surged to CNY 448.39 million, a significant increase of 80.45% due to improved operations and procurement services[41]. - The core product, Anshen Bnnao Liquid, generated sales of CNY 616.25 million, reflecting a steady growth trend over the past 40 years[46]. - The "Children's Chai Gui Fever Oral Liquid" product has become a first-line medication for pediatric respiratory diseases, recognized for its high cure rate and low recurrence[187]. - The "Blood Mansion Dispersing Oral Liquid" is a unique innovative traditional Chinese medicine, recognized for its scientific achievements and market acceptance[188]. Corporate Governance and Management - The company has established a robust investor relations management system to enhance communication and maintain stakeholder interests[28]. - The company maintains an independent business system and operational capability, ensuring independence from its controlling shareholders[30]. - The company has implemented strict insider information management practices to prevent leaks and ensure compliance with regulations[29]. - The company has a comprehensive governance structure in place to ensure compliance with regulatory requirements and maintain operational integrity[36]. - The company emphasizes a modern corporate governance structure, implementing a parent-subsidiary management system to enhance operational efficiency[96]. - The company has a robust governance structure with effective checks and balances through its shareholder meetings and board systems[60]. Research and Development - The company is actively pursuing the development of traditional Chinese medicine formula granules, aiming to achieve market sales volume by collaborating with renowned universities and hospitals[18]. - The company plans to enhance its product development by integrating traditional Chinese medicine concepts with modern technology, leveraging its national and provincial research centers[19]. - The company focuses on a market-oriented approach in R&D, combining traditional Chinese medicine concepts with modern technology to enhance product quality and clinical application[66]. - The company has optimized its production model, transitioning towards automation, information technology, and digitalization to enhance traditional Chinese medicine manufacturing[65]. - The company has implemented advanced manufacturing technologies, including automated production lines and modern biopharmaceutical techniques, to enhance production efficiency and quality, transitioning towards intelligent and digital manufacturing[193]. Social Responsibility and Environmental Compliance - The company has actively engaged in social responsibility initiatives, including a CNY 3 million investment in an ecological project and CNY 2 million in donations for poverty alleviation[132]. - Environmental protection investments for 2022 totaled CNY 3,488,335.21, with specific contributions from subsidiaries for environmental projects[129]. - The company has maintained compliance with environmental regulations, with no significant penalties reported during the period[131]. - The company is committed to green development in the traditional Chinese medicine industry, ensuring clean production and sustainable resource utilization[65]. Employee Relations and Stock Ownership - The company has established a complete system for labor, personnel, and salary management, with an independent human resources department[2]. - The company is committed to providing competitive salary and welfare packages to employees, aligning compensation with performance and market trends[108]. - The employee stock ownership plan saw 39 holders exit due to contract termination, with their shares being reclaimed and original contributions returned[89]. - The company has implemented an employee stock ownership plan with a lock-up period of 36 months, with a minimum selling price of CNY 32 per share post-lock-up[117]. - The first employee stock ownership plan involved the transfer of 19,809,743 shares to the plan's account on December 30, 2016[141]. Market Strategy - The sales strategy includes a diversified marketing model, integrating online and offline channels to expand sales networks and boost performance[65]. - The company actively explores modern sales methods, including e-commerce and live streaming, to enhance its market presence[65]. - The company has established a procurement model that leverages its advantages in the pharmaceutical industry to improve quality and efficiency while reducing costs[96]. Risk Management - The company faces environmental protection risks due to strict regulatory requirements in the pharmaceutical manufacturing industry, which could impact normal operations[22]. - There is a risk that fundraising projects may not achieve expected returns despite thorough market research and preparations in technology, personnel, and sales channels[24]. - The company has established a comprehensive internal control system to enhance management and risk prevention capabilities[119]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties during the reporting period[159].

关于举办2022年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 吉林敖东药业集团股份有限公司（以下简称"公司"）2022年年度报告已于 2023年4月19日公布，为了让广大投资者进一步了解公司2022年度报告和经营情 况，公司将于2023年4月24日（星期一）下午15:00－17:00通过深圳市全景网络 有限公司提供的互联网平台举行2022年度业绩说明会，本次年度业绩说明会将采 用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平台" （http://ir.p5w.net）参与本次年度业绩说明会。 届时公司副董事长、总经理郭淑芹女士，独立董事毕焱女士，董事、副总经 理、财务总监张淑媛女士，董事、副总经理、董事会秘书王振宇先生，将通过网 络在线问答互动的形式，与投资者就2022年度经营业绩等投资者关注的问题进行 交流。期间，公司高级管理人员将全程在线，实时回答投资者的提问。 为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于2023年4月 20日（星期四 ...